Takeda's ENTYVIO Receives FDA Acceptance for Pediatric Use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 10 2026
0mins
Source: NASDAQ.COM
- FDA Application Acceptance: Takeda's supplemental Biologics License Application for ENTYVIO (vedolizumab) targeting moderately to severely active ulcerative colitis and Crohn's disease in pediatric patients aged 2 and older has been accepted by the FDA, with a PDUFA date expected in Q1 2027, indicating the company's strategic focus on pediatric IBD treatment.
- Market Expansion Plans: In addition to the U.S., Takeda has submitted a marketing authorization application for ENTYVIO IV to the European Medicines Agency and plans to submit applications in additional markets later this year, demonstrating the company's commitment to global market expansion and enhancing its competitiveness in the biopharmaceutical sector.
- Clinical Trial Support: The application is supported by data from two randomized, double-blind, multicenter Phase 3 trials in patients aged 2 to 17, namely the KEPLER study for UC and the ongoing WEBB study for Crohn's disease, showcasing ENTYVIO's efficacy and safety in pediatric patients and bolstering market acceptance.
- Financial Performance: For the fiscal year ending March 31, 2026, global revenue for ENTYVIO increased by 4.8% to 958 billion yen, reflecting sustained demand for the product and the company's robust performance in the IBD treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.420
Low
18.00
Averages
18.00
High
18.00
Current: 15.420
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction: Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, providing a substantial non-dilutive capital infusion that significantly strengthens its financial position.
- Product Background: The PRV was granted following the FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) in March 2026 for treating Hunter syndrome, highlighting the drug's market potential and the company's competitiveness in the rare disease sector.
- Advancing Clinical Portfolio: The capital infusion will aid Denali in advancing its broad Transport Vehicle-enabled clinical portfolio focused on lysosomal storage disorders and neurodegenerative diseases, further solidifying its position in the biopharmaceutical industry.
- Collaborations and R&D: Denali collaborates with pharmaceutical giants like Sanofi, Biogen, and Takeda to develop various candidates, and despite the discontinuation of the BIIB122 project with Biogen due to unmet expectations, the company will continue to independently advance other key studies, demonstrating resilience and promising prospects in its R&D efforts.
See More
Takeda Reports New Data on Oveporexton for Type 1 Narcolepsy
- Clinical Trial Results: Takeda's Phase 3 FirstLight and RadiantLight trials involved 168 and 105 patients globally, respectively, demonstrating significant improvements in daily functioning, indicating the potential of Oveporexton in treating Type 1 Narcolepsy.
- Cognitive Function Improvement: In the FINI cognitive function assessment, over 70% of patients reported no cognitive difficulties after dosing Oveporexton, compared to only 15% in the placebo group, highlighting the drug's effectiveness in enhancing cognitive symptoms.
- FDA Priority Review: The FDA has accepted the new drug application for Oveporexton under priority review, with results expected in the third quarter of this year, which could open new market opportunities for Takeda in the narcolepsy treatment space.
- International Regulatory Applications: In addition to the U.S., Takeda has filed for regulatory approval of Oveporexton in China and Japan, reflecting its strategic intent to expand globally and meet the growing patient demand.
See More
Takeda Unveils New Narcolepsy Drug Study Results
- Clinical Study Results: Takeda presented pivotal study results at SLEEP 2026, indicating that its drug oveporexton significantly improves daily functioning and cognitive and sleep-related symptoms in patients with narcolepsy type 1, highlighting its potential in the treatment landscape.
- Redefining Standard Care: The data, along with previously disclosed Phase 3 results, suggest that oveporexton could redefine the standard of care for narcolepsy type 1, enhancing patient quality of life and addressing unmet medical needs in this area.
- Regulatory Review Progress: Sarah Sheikh from Takeda stated that oveporexton is under review by multiple regulatory agencies, and if approved, it would be the first and only orexin agonist, representing a significant breakthrough in the treatment field.
- Stock Price Movement: Despite the positive drug study results, Takeda's shares fell by 2.18%, currently trading at 4,977 yen, reflecting market caution regarding the drug's approval prospects.
See More
Takeda Presents Oveporexton Study Results at SLEEP 2026
- Significant Efficacy Improvement: At SLEEP 2026, Takeda reported that Oveporexton significantly improved daily functioning in narcolepsy patients across two pivotal Phase 3 studies, with all doses showing significant superiority over placebo (p<0.001) at week 12, indicating the drug's potential to redefine the standard of care for narcolepsy.
- Cognitive Function Enhancement: Oveporexton demonstrated a notable improvement in cognitive symptoms associated with narcolepsy, with approximately 70% of patients across all doses reporting no significant cognitive difficulties compared to about 15% in the placebo group, highlighting the drug's potential to enhance patients' quality of life.
- Nighttime Sleep Quality Improvement: The studies revealed that Oveporexton significantly improved nighttime sleep quality, with most patients reporting no hallucinations or sleep paralysis, particularly those on the 2mg dose, who experienced meaningful reductions in disturbed nighttime sleep, thus providing a better sleep experience for patients.
- Regulatory Review Progress: The New Drug Application for Oveporexton has been accepted by the FDA for Priority Review, with a goal date in the third quarter of this year, marking a significant milestone for Takeda in the narcolepsy treatment landscape and potentially offering revolutionary treatment options for patients.
See More
Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial
- Clinical Trial Success: Takeda's tyrosine kinase inhibitor, zasocitinib, significantly outperformed the rival therapy Sotyktu in the LATITUDE trial, with over 35% of patients achieving complete skin clearance, more than 2.5 times higher than Sotyktu, indicating its strong therapeutic potential.
- Safety Profile: The trial reported no new safety concerns, and zasocitinib was well tolerated, consistent with prior studies, which supports its future marketability and acceptance among healthcare providers.
- Market Application Plans: Takeda intends to submit marketing applications for zasocitinib to the U.S. FDA and other regulatory agencies within this fiscal year, aiming to capitalize on its promising results in psoriasis treatment.
- Future Data Presentation: The company plans to present full LATITUDE trial data at an upcoming medical event, which will provide deeper insights for investors and the medical community, thereby enhancing market confidence.
See More
Zasocitinib Shows Superiority in Psoriasis Study
- Clinical Trial Results: In a Phase 3 trial for moderate-to-severe plaque psoriasis, zasocitinib (TAK-279) achieved over 35% complete skin clearance (PASI 100) at week 16, which is 2.5 times the response rate of deucravacitinib, demonstrating significant efficacy superiority.
- Safety Profile: The safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified, indicating good tolerability for long-term use and providing a safer treatment option for patients.
- Future Development Plans: Takeda plans to present detailed data at upcoming medical congresses and expects to submit a New Drug Application to the FDA for plaque psoriasis this fiscal year, further advancing zasocitinib's market entry.
- Market Potential: As a next-generation TYK2 inhibitor with over 1 million-fold selectivity, zasocitinib has the potential to become the preferred oral treatment option for psoriasis patients, addressing the growing market demand.
See More
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction: Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, providing a substantial non-dilutive capital infusion that significantly strengthens its financial position.
- Product Background: The PRV was granted following the FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) in March 2026 for treating Hunter syndrome, highlighting the drug's market potential and the company's competitiveness in the rare disease sector.
- Advancing Clinical Portfolio: The capital infusion will aid Denali in advancing its broad Transport Vehicle-enabled clinical portfolio focused on lysosomal storage disorders and neurodegenerative diseases, further solidifying its position in the biopharmaceutical industry.
- Collaborations and R&D: Denali collaborates with pharmaceutical giants like Sanofi, Biogen, and Takeda to develop various candidates, and despite the discontinuation of the BIIB122 project with Biogen due to unmet expectations, the company will continue to independently advance other key studies, demonstrating resilience and promising prospects in its R&D efforts.
See More
Takeda Reports New Data on Oveporexton for Type 1 Narcolepsy
- Clinical Trial Results: Takeda's Phase 3 FirstLight and RadiantLight trials involved 168 and 105 patients globally, respectively, demonstrating significant improvements in daily functioning, indicating the potential of Oveporexton in treating Type 1 Narcolepsy.
- Cognitive Function Improvement: In the FINI cognitive function assessment, over 70% of patients reported no cognitive difficulties after dosing Oveporexton, compared to only 15% in the placebo group, highlighting the drug's effectiveness in enhancing cognitive symptoms.
- FDA Priority Review: The FDA has accepted the new drug application for Oveporexton under priority review, with results expected in the third quarter of this year, which could open new market opportunities for Takeda in the narcolepsy treatment space.
- International Regulatory Applications: In addition to the U.S., Takeda has filed for regulatory approval of Oveporexton in China and Japan, reflecting its strategic intent to expand globally and meet the growing patient demand.
See More
Takeda Unveils New Narcolepsy Drug Study Results
- Clinical Study Results: Takeda presented pivotal study results at SLEEP 2026, indicating that its drug oveporexton significantly improves daily functioning and cognitive and sleep-related symptoms in patients with narcolepsy type 1, highlighting its potential in the treatment landscape.
- Redefining Standard Care: The data, along with previously disclosed Phase 3 results, suggest that oveporexton could redefine the standard of care for narcolepsy type 1, enhancing patient quality of life and addressing unmet medical needs in this area.
- Regulatory Review Progress: Sarah Sheikh from Takeda stated that oveporexton is under review by multiple regulatory agencies, and if approved, it would be the first and only orexin agonist, representing a significant breakthrough in the treatment field.
- Stock Price Movement: Despite the positive drug study results, Takeda's shares fell by 2.18%, currently trading at 4,977 yen, reflecting market caution regarding the drug's approval prospects.
See More
Takeda Presents Oveporexton Study Results at SLEEP 2026
- Significant Efficacy Improvement: At SLEEP 2026, Takeda reported that Oveporexton significantly improved daily functioning in narcolepsy patients across two pivotal Phase 3 studies, with all doses showing significant superiority over placebo (p<0.001) at week 12, indicating the drug's potential to redefine the standard of care for narcolepsy.
- Cognitive Function Enhancement: Oveporexton demonstrated a notable improvement in cognitive symptoms associated with narcolepsy, with approximately 70% of patients across all doses reporting no significant cognitive difficulties compared to about 15% in the placebo group, highlighting the drug's potential to enhance patients' quality of life.
- Nighttime Sleep Quality Improvement: The studies revealed that Oveporexton significantly improved nighttime sleep quality, with most patients reporting no hallucinations or sleep paralysis, particularly those on the 2mg dose, who experienced meaningful reductions in disturbed nighttime sleep, thus providing a better sleep experience for patients.
- Regulatory Review Progress: The New Drug Application for Oveporexton has been accepted by the FDA for Priority Review, with a goal date in the third quarter of this year, marking a significant milestone for Takeda in the narcolepsy treatment landscape and potentially offering revolutionary treatment options for patients.
See More
Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial
- Clinical Trial Success: Takeda's tyrosine kinase inhibitor, zasocitinib, significantly outperformed the rival therapy Sotyktu in the LATITUDE trial, with over 35% of patients achieving complete skin clearance, more than 2.5 times higher than Sotyktu, indicating its strong therapeutic potential.
- Safety Profile: The trial reported no new safety concerns, and zasocitinib was well tolerated, consistent with prior studies, which supports its future marketability and acceptance among healthcare providers.
- Market Application Plans: Takeda intends to submit marketing applications for zasocitinib to the U.S. FDA and other regulatory agencies within this fiscal year, aiming to capitalize on its promising results in psoriasis treatment.
- Future Data Presentation: The company plans to present full LATITUDE trial data at an upcoming medical event, which will provide deeper insights for investors and the medical community, thereby enhancing market confidence.
See More
Zasocitinib Shows Superiority in Psoriasis Study
- Clinical Trial Results: In a Phase 3 trial for moderate-to-severe plaque psoriasis, zasocitinib (TAK-279) achieved over 35% complete skin clearance (PASI 100) at week 16, which is 2.5 times the response rate of deucravacitinib, demonstrating significant efficacy superiority.
- Safety Profile: The safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified, indicating good tolerability for long-term use and providing a safer treatment option for patients.
- Future Development Plans: Takeda plans to present detailed data at upcoming medical congresses and expects to submit a New Drug Application to the FDA for plaque psoriasis this fiscal year, further advancing zasocitinib's market entry.
- Market Potential: As a next-generation TYK2 inhibitor with over 1 million-fold selectivity, zasocitinib has the potential to become the preferred oral treatment option for psoriasis patients, addressing the growing market demand.
See More
